文献速递鼻科

肿瘤坏死因子α抑制剂治疗患者的鼻窦炎

Sinusitis in patients on tumor necrosis factor alpha inhibitors.
PubMed 文献 · Int Forum Allergy Rhinol · 2016-12-13

该研究回顾性分析了杜克大学28例接受肿瘤坏死因子α(TNF-α)抑制剂并由耳鼻咽喉科医生诊断鼻窦炎的患者病历,发现耳鼻咽喉科诊断并治疗的鼻窦炎患病率低于1%,其中57.1%为新发鼻窦炎,71.4%诊断为慢性鼻窦炎不伴鼻息肉(CRSsNP),主要累及上颌窦和筛窦,无患者出现严重窦外并发症或需住院或静脉抗生素治疗,35.7%需手术干预,14.3%在停用、更换或暂停TNF-α抑制剂后鼻窦症状改善。

要点

  • 接受TNF-α抑制剂者中由耳鼻咽喉科诊断并治疗的鼻窦炎患病率低于1%。
  • 28例中57.1%为新发鼻窦炎,71.4%为CRSsNP,主要累及上颌窦和筛窦。
  • 无严重窦外并发症或需住院/静脉抗生素者;35.7%需手术,14.3%调整TNF-α抑制剂后症状改善。

核心结论

  • 抗TNF-α治疗可能与新发鼻窦炎相关,主要为CRSsNP。
  • 接受TNF-α抑制剂的患者中寻求耳鼻咽喉科会诊的比例较低。
  • 部分新发鼻窦炎患者需要手术,调整抗TNF-α治疗可作为这些患者内科管理的选项之一。

研究设计与样本

  • 回顾性病历审查,纳入杜克大学28例接受TNF-α抑制剂并由耳鼻咽喉科医生诊断鼻窦炎的患者。
  • 研究患者人口学特征、鼻窦炎特征及治疗过程。

主要发现

  • 由耳鼻咽喉科诊断并治疗的鼻窦炎患病率低于1%。
  • 28例中12例(42.9%)有既往鼻窦炎病史,16例(57.1%)为新发鼻窦炎。
  • 71.4%诊断为慢性鼻窦炎不伴鼻息肉(CRSsNP),病变主要累及上颌窦和筛窦。
  • 无患者出现严重窦外并发症或需要住院或静脉抗生素治疗。
  • 35.7%(n=10)在启动抗TNF治疗后需要手术干预,其中新发患者为44%(7/16)。

临床怎么用

  • 作者认为,抗TNF-α治疗可能与新发鼻窦炎相关,主要为CRSsNP。
  • 作者认为,部分新发鼻窦炎患者需要手术,调整抗TNF-α治疗可作为这些患者内科管理的选项之一。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor necrosis factor alpha (TNF-α) inhibitors have revolutionized treatment of many inflammatory diseases. Sinusitis after initiation of TNF-α inhibitors has been observed, but has not been well described in the literature. We aim to characterize the clinical features of sinusitis in patients on anti-TNF-α therapy. METHODS: This is a retrospective chart review of 28 patients on a TNF-α inhibitor diagnosed with sinusitis by otolaryngologists at Duke University. Patient demographics, sinusitis characteristics, and treatment course were studied by chart review. RESULTS: The prevalence of sinusitis diagnosed and treated by an otolaryngologist was less than 1%. Of the 28 patients studied, 12 (42.9%) had a history of preexisting sinusitis and 16 (57.1%) had new-onset sinusitis. 71.4% were diagnosed with chronic rhinosinusitis without polyps (CRSsNP), with disease mainly involving the maxillary and ethmoid sinuses. No patients had major extrasinus complications or required hospital admission or intravenous (IV) antibiotics. 35.7% (n = 10), including 44% (7/16) of new-onset patients required a surgical intervention after initiating anti-TNF therapy. 14.3% (n = 4) of the cohort had improvement in sinonasal symptoms after stopping, changing, or holding doses of the TNF-α inhibitor. CONCLUSION: Anti-TNF-α therapy can be associated with new-onset sinusitis, mainly CRSsNP. Overall, the percentage of patients on a TNF-α inhibitor seeking consultation from an otolaryngologist is low. While some patients with new-onset sinusitis will require surgery, modification of anti-TNF-α therapy should be considered as an option in the medical management of these patients.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Wang CS, Honeybrook A, Chapurin N, et al. Sinusitis in patients on tumor necrosis factor alpha inhibitors. Int Forum Allergy Rhinol. 2016. PMID: 27958666. doi:10.1002/alr.21895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。